



SD12
Rawlings

A Docket: 59866.000002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:)

M. N. Holten-Andersen et al.)

Serial No.: 09/546,573)

Filed: April 10, 2000)

Art Unit: 1642

Examiner: S. Rawlings

For: TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES
TYPE-1 (TIMP-1) AS A CANCER MARKER

RECEIVED

AUG 23 2001

TECH CENTER 1600/2900

Handwritten initials and marks, including a large 'A' and 'S'.

Handwritten number 9501

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicants respectfully request consideration of the references listed on the attached Form PTO/SB/08A.

Applicants submit this Supplemental Information Disclosure Statement ("Supplemental IDS") pursuant to a recent telephone conversation with Mr. Rawlings, the Examiner responsible for the application. Mr. Rawlings acknowledged receipt of an IDS filed on June 26, 2001, but requested that Applicants file a Supplemental IDS listing on an appropriate form all the references identified in the International Search Report submitted with the June 26th IDS. Mr. Rawlings also confirmed that the references were received with the June 26th IDS, and no additional copies thereof were needed.

Applicants respectfully request that the Examiner consider the references cited on the Form PTO/SB/08A and that the Examiner indicate that the references have been considered



21967

PATENT TRADEMARK OFFICE


in this application by returning a copy of the Form PTO/SB/08A with the Examiner's initials in the left column per MPEP 609.

Applicants respectfully point out that the submission of the references is not an admission that they are prior art or that they are material to patentability of any claims of the application. Also, the submission of the June 26th IDS or Supplemental IDS is not an indication that a search has been made.

This Supplemental IDS is submitted prior to the issuance of a first Office Action on the merits; therefore, it is believed that no fees are required in connection therewith. If any fees are necessitated by the filing of this Information Disclosure Statement, please charge the undersigned's Deposit Account No. 50-0206.

Date: August 20, 2001

Respectfully submitted,
HUNTON & WILLIAMS



Stanislaus Aksman
Registration No. 28,562

1900 K Street, N.W., Suite 1200
Washington, D.C. 20006-1109
Ph. (202) 955-1500
Fax (202) 778-2201